Subscribe to RSS
Myocardial nulling pattern in cardiac amyloidosis on time of inversion scout magnetic resonance imaging sequence – A new observation of temporal variability
Subject Editor: Financial support and sponsorship Nil.
Context: The pattern of myocardial nulling in the inversion scout sequence [time of inversion scout (TIS)] of cardiac magnetic resonance imaging (MRI) is an accurate tool to detect cardiac amyloidosis. The pattern of nulling of myocardium and blood at varying times post gadolinium injection and its relationship with left ventricular mass (LVM) in amyloidosis have not been described previously. Aims: The aim is to study the nulling pattern of myocardium and blood at varying times in TIS and assess its relationship with LVM and late gadolinium enhancement (LGE) in amyloidosis. Materials and Methods: This was a retrospective study of 109 patients with clinical suspicion of cardiac amyloidosis who underwent MRI. Of these, 30 had MRI features of amyloidosis. The nulling pattern was assessed at 5 (TIS5min) and 10 (TIS10min) minutes (min) post contrast injection. Nulling pattern was also assessed at 3min (TIS3min) in four patients and 7min (TIS7min) in five patients. Myocardial mass index was calculated. Mann-Whitney U test was done to assess statistical difference in the myocardial mass index between patients with and without reversed nulling pattern (RNP) at TIS5min. Results: RNP was observed in 58% at TIS5minand 89.6% at TIS10min. Myocardial mass index was significantly higher in patients with RNP at TIS5min[mean = 94.87 g/m2; standard deviation (SD) =17.63) when compared with patients with normal pattern (mean = 77.61 g/m2; SD = 17.21) (U = 18; P = 0.0351). Conclusion: In cardiac amyloidosis, TIS sequence shows temporal variability in nulling pattern. Earlier onset of reverse nulling pattern shows a trend toward more LVM and possibly more severe amyloid load.
26 July 2021 (online)
© 2018. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Hazenberg BPC. Amyloidosis. Rheum Dis Clin N Am 2013; 39: 323-45
- 2 Lee M-H, Lee S-P, Kim Y-J, Sohn D-W. Incidence, diagnosis and prognosis of cardiac amyloidosis. Korean Circ J 2013; 43: 752-60
- 3 Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I. et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186-93
- 4 Pandey T, Jambhekar K, Shaikh R, Lensing S, Viswamitra S. Utility of the inversion scout sequence (TI scout) in diagnosing myocardial amyloid infiltration. Int J Cardiovasc Imaging 2013; 29: 103-12
- 5 Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging 2014; 7: 552-62
- 6 Vogel-Claussen J, Rochitte CE, Wu KC, Kamel IR, Foo TK, Lima JAC. et al. Delayed enhancement MR imaging: Utility in myocardial assessment. RadioGraphics 2006; 26: 795-810
- 7 van den Driesen RI, Slaughter RE, Strugnell WE. MR findings in cardiac amyloidosis. Am J Roentgenol 2006; 186: 1682-5
- 8 Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S. et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022-30
- 9 Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: A systematic review and meta-analysis. BMC Cardiovasc Disord 2016; 16: 129
- 10 Austin BA, Tang WHW, Rodriguez ER, Tan C, Flamm SD, Taylor DO. et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009; 2: 1369-77
- 11 Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S-I. et al. A primer of amyloid nomenclature. Amyloid 2007; 14: 179-83
- 12 Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: A review. J Am Heart Assoc 2012; 1: e000364
- 13 Kristen AV, Brokbals E, Aus dem Siepen F, Bauer R, Hein S, Aurich M. et al. Cardiac amyloid load: A prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 2016; 68: 13-24
- 14 Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J. et al. Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985; 6: 737-43
- 15 Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10: 54
- 16 Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM. et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-7
- 17 aus dem Siepen F, Kammerer R, Scherer KA, Bauer R, Hardt SE, Giannitsis E. et al. Thickness of the midventricular left ventricular wall is predictive of survival in different forms of cardiac amyloidosis. J Cardiovasc Magn Reson 2013; 15 (01) P93
- 18 Baroni M, Nava S, Quattrocchi G, Milazzo A, Giannattasio C, Roghi A. et al. Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: Late gadolinium enhancement pattern as mortality predictor. Neth Heart J 2018; 26: 34-40
- 19 Raina S, Lensing SY, Nairooz RS, Pothineni NVK, Hakeem A, Bhatti S. et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. JACC Cardiovasc Imaging 2016; 9: 1267-77
- 20 Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM. et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015; 132: 1570-9
- 21 White JA, Kim HW, Shah D, Fine N, Kim K-Y, Wendell DC. et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 2014; 7: 143-56
- 22 Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM. et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6: 488-97
- 23 Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A. et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015; 36: 244-51
- 24 Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323: 508-13
- 25 From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc 2011; 86: 1095-102